Introduction: Although intravesical Bacille Calmette Guerin therapy for high grade superficial bladder cancer is not specifically contra indicated in people with asymptomatic bacteriuria, generally urologist are reluctant in administering this to such patients because of a possible risk of bacterial sepsis or BCG sepsis.On the other hand,anti bacterial treatment of asymptomatic bacteriuria leads to treatment delay and promotes tumour progresssion. This study is done to investigate whether intravesical BCG therapy alone can eradicate bacterial infection in asymptomatic bactreriuric patients on intravesical BCG therapy for bladder tumour. Methods: A Single institutional prospective cohort study of bacteriuric adults with non muscle invasive bladder cancer who underwent outpatient based BCG intravesical therapy from November 2020 to November 2021 were followed up for one year till November 2022. 25 High grade non muscle invasive bladder cancer patients who underwent intravesical BCG therapy were compared with 25 low grade non muscle invasive bladder cancer patients. All patients had asymptomatic bacteriuria,none recieved antibiotic therapy before ,during or after cystoscopy procedure .Urine culture were repeated after 3,6 and 12 months after completion of one year post TURBT. All patients were followed up for a minimum of one year. The end point was number of patients who became bacteria free at 3,6,12 months. Results: None of BCG treated patients ,but three control patients developed febrile urinary tract infections and were removed from the study. Of the study group out of 25 patients who recieved intravesical BCG 20 were continuously bacteria free at the end of one year compared with 8 out of 22 patients in the control group. Conclusions: Intravesical BCG is associated with clearance of Uropathogens in bladder cancer patients possibly due to an augmented innate host immunity. SOURCE OF Funding: Self (Author)
